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practice, and have some of the initia-
tives they have undertaken redounded
to the detriment of physicians and pa-
tients?
Fundamental questions deserve care-
ful reflection and wide debate. Is there a
direct or inverse correlation between
the time and effort required to meet
accreditation requirements and the
quality of educational programs? As-
suming that some regulation is good but
a lot of regulation is bad—a graph of this
function would demonstrate an inflec-
tion point—how would we know when
we were approaching or had passed
that point? What is the quality of the
evidence on which accrediting organiza-
tions base their dicta, and what efforts
are they making to collect, analyze, and
disseminate the results? No one con-
tests that oversight is needed. But mere
oversight is not good oversight, nor is
more oversight necessarily better over-
sight.
Perhaps the overseers should de-
vote less effort to telling bright, cre-
ative, and energetic educators, who
are busier and operating under tighter
resource constraints than ever before,
what they must do and how they must
do it and instead devote a bit more
effort to listening, learning, and dis-
seminating best practices. Does any-
one seriously think that the vast ma-
jority of radiology residency and fel-
lowship programs are defaulting on
their fiduciary responsibility to edu-
cate qualified physicians who will pro-
vide good patient care? We need to be
reaching for the stars, not proving that
we are standing on the ground. Who
oversees the overseers?
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Editor:
I read with interest the article by Dr Uto
and colleagues (1) in the July 2009 issue
of Radiology, which examined the utility
of the lesion-to–spinal cord ratio (LSR)
for characterization of pulmonary lesions
on high–b value diffusion-weighted (DW)
magnetic resonance (MR) images. The
authors deserve to be congratulated for
introducing such a practical method.
However, some issues need to be ad-
dressed to help readers better under-
stand the study.
The title of the article is misleading
because the specificity (90%) is the
same for apparent diffusion coefficient
(ADC) and LSR measurements. “Higher
accuracy” instead of “higher sensitivity
and specificity” would be more correct.
Furthermore, there are miscalcula-
tions of the predictive values of LSR for
a cutoff value of 1.135 in the Results and
in table 2. The positive and negative
predictive values should be 93.8% (15
of 16) and 75% (nine of 12), respec-
tively.
I think the lower accuracy of ADC
(50% vs 85.7% for LSR) in their study
may have resulted from the small pa-
tient population with a high proportion
(11 of 18) of adenocarcinoma. In a
larger series encompassing 140 pulmo-
nary lesions, Mori et al (2) reported
that DW MR imaging has accuracy
(76%) comparable to that (74%) of
positron emission tomography with a b
value of 1000 sec/mm2. However, with
an ADC cutoff value of 1.1 103 mm2,
39.6% (21 of 53) of well-differentiated
adenocarcinomas had negative findings
on DW MR images in their series, com-
pared with 4.7% (one of 21) of squa-
mous cell carcinomas. Tumor cellularity
is lower in well-differentiated adenocar-
cinoma, accounting for less restriction
in diffusion and resulting in higher ADC
values (3). Adenocarcinoma was also
identified as a cause of three false-nega-
tive cases when using LSR in the series
of Dr Uto and colleagues (1).
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We thank Dr Karabulut for pointing out
some miscalculations that appeared in
our article (1). His statement is reason-
able that the positive and negative pre-
dictive values should be 93.8% (15 of
16) and 75% (nine of 12), respectively.
The title should have been “Higher Sensi-
tivity and Comparable Specificity for Dif-
fusion-weighted Imaging of Malignant
Lung Lesions without Apparent Diffu-
sion Coefficient Quantification.” Al-
though he was concerned about the
title, we feel our core message will be
understood by readers of Radiology.
To date, some studies (2–4) have
shown that DW imaging is important
in helping to diagnose various cancers,
and most of the studies have used the
ADC. However, current techniques
for calculating ADC are not sufficiently
mature to provide consistent values,
particularly in the torso area. This is
mainly because of the inherent prob-
lems of echo-planar imaging (we will
not repeat the individual problems in
this reply). The core problem we in-
tended to address in our study is the
inconsistency in ADC calculation with
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current techniques. If the perfor-
mance is comparable, our simpler and
more practical method will be pre-
ferred by radiologists.
Dr Karabulut also provided impor-
tant information to us by referring to
the study of Mori et al (5). Differenti-
ation of adenocarcinoma with DW im-
aging is challenging because of the low
cellularity in the tumor. Dr Karabulut
suggested that the improved results
with our method might be owing to the
small patient population and the high
proportion of adenocarcinomas. The
improved differentiation of adenocarci-
noma that we reported may reflect the
robustness of our new index, LSR, as
compared with ADC. We suggest that
Mori et al should measure LSR and assess
its performance in comparison to ADC.
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Errata
“Does Arterial Spin-labelingMR Imaging–
measured Tumor Perfusion Correlate
with Renal Cell Cancer Response to Anti-
angiogenic Therapy in a Mouse Model?”
Radiology 2009;251(3):731–742
On page 735, Figure 3, the left im-
age in the third row is incorrect. The
correct image is shown below, and ar-
rows indicate copious microvascula-
ture.
“Pulmonary Embolism Detection with
Dual-Energy CT: Experimental Study of
Dual-Source CT in Rabbits.” Radiology
2009;252(1):61–70
Page 62, the second sentence of the
second paragraph should read as follows:
In technologic terms, it is difficult to eval-
uate microcirculation of the whole lung
with earlier-generation CT scanners,
including single-source 64-section CT
units, because of postprocessing time and
misregistration artifacts between two spi-
ral scanners (8–14).
Page 63, the first sentence under “Im-
age Reconstruction and Analysis” should
read as follows: From the raw spiral pro-
jection data acquired with both x-ray
tubes, images were automatically recon-
structed into three data sets (an 80-kVp
data set, a 140-kVp data set, and a data
set of fused images with 30% attenuation
information from the 80-kVp scan and
70% attenuation information from the
140-kVp scan) with a 0.75-mm section
thickness and a 0.50-mm section interval
(33% overlap).
Page 68, left column, the first full
sentence should read as follows: Our
pilot study with rabbits showed that BF
imaging alone had a diagnostic sensi-
tivity of 89% in the detection of PE
and had good agreement with patho-
logic analysis.
“Carotid Artery Brain AneurysmModel:
In Vivo Molecular Enzyme-specific MR
Imaging of Active Inflammation in a Pi-
lot Study.” Radiology 2009;252(3):696–
703
Page 696, the fourth sentence of Ma-
terials and Methods should read as fol-
lows: After intraarterial injection of an
MPO-specific (di-5-hydroxytryptamide of
gadopentetate dimeglumine, 0.1 mmol
per kilogram of bodyweight) or a non–
MPO-specific (dityramide of gado-
pentetate dimeglumine, 0.1 mmol/kg)
contrast agent, animals underwent 3-T
MR imaging.
Page 696, the third sentence of Re-
sults should read as follows: In inflamed
aneurysms, di-5-hydroxytryptamide of
gadopentetate dimeglumine exhibited de-
layed washout kinetics compared with
the kinetics of dityramide of gado-
pentetate dimeglumine.
Page 698, the first sentence under
“MPO-specific andNon–MPO-specificCon-
trast Agents” should read as follows: An
author (A.A.B., 18 years of experience)
performed synthesis of MPO-specific (di-5-
hydroxytryptamide of gadopentetate dime-
glumine) and non–MPO-specific (dityra-
mide of gadopentetate dimeglumine) MR
contrast agents, as described previously
(24,25), with slight modifications.
Page 698, right column, the third full
sentence should read as follows: Animals
were then injected with a sterile solution
of 0.1 mmol/kg of di-5-hydroxytrypt-
amide of gadopentetate dimeglumine or
dityramide of gadopentetate dimeglu-
mine in 15 mL of 5% meglumine with a
pH of 7.
Page 698, right column, the fifth full
sentence should read as follows: Time
course experiments were performed up
to 330 minutes after contrast agent injec-
tion with the same imaging parameters
described previously after administration
of either di-5-hydroxytryptamide of gado-
pentetate dimeglumine or dityramide of
gadopentetate dimeglumine in animals
with aneurysms into which LPS had been
injected.
Page 699, the first sentence under
“Sensitivity and Specificity for MPO in In-
flamed Aneurysms” should read as fol-
lows: The kinetics of enhancement of the
aneurysm and left CCA with both di-5-
hydroxytryptamide of gadopentetate
dimeglumine and dityramide of gado-
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pentetate dimeglumine are shown in Fig-
ure 3.
Page 699, the third sentence under
“Sensitivity and Specificity for MPO in In-
flamed Aneurysms” should read as fol-
lows: Both the inflamed aneurysm and
the left CCA in the animal that received
dityramide of gadopentetate dimeglu-
mine had similar enhancement ratios mea-
sured at each point of the time course.
Page 701, the caption for figure 3
should read as follows: Figure 3: Graphs
show kinetics of enhancement of (a) a
representative LPS-injected aneurysm
and (b) the left CCA. The enhancement
ratio (ER) of di-5-hydroxytryptamide of
gadopentetate dimeglumine (di-5-HT-
GdDTPA) is compared with that of
dityramide of gadopentetate dimeglu-
mine (di-Tyr-GdDTPA).
Page 702, left column, second para-
graph, the third sentence should read as
follows: We compared the observed en-
hancement ratio with that of dityramide
of gadopentetate dimeglumine, which is a
contrast agent that is structurally simi-
lar to di-5-hydroxytryptamide of gado-
pentetate dimeglumine and has been
demonstrated in vitro to be activated by
peroxidases but not by MPO (24).
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